IGCS Home
Education360 Home

Master Session: Cervix Cancer

  • Chairs: Bradley Monk (USA), Mary McCormack (UK), Ana Oaknin (Spain)
  • Histologic Subtypes & Molecular Features: Kathleen Moore (USA)
  • Staging: Jalid Sehouli (Germany)
  • State of the Science in Radiation Therapy: Alexandra Taylor (UK)
  • Addition Systemic Therapy to Radiation (CCRT): Linda Mileshkin (Australia)
  • Firstline Treatment of Metastatic Disease: Leslie Randall (USA)
  • Second-Line Metastatic Disease: Krishnansu Tewari (USA)
  • Clinical Care in Under-Resourced Settings & How To Start A Clinical Trials Program: Marie Plante (Canada)

Master Session: Ovarian Cancer

  • Welcome Chairs: Robert Coleman (USA), Nicoletta Colombo (Italy), Douglas Levine (USA)
  • How to Subclassify Ovarian Carcinoma into Hystotypes & Molecular Subtypes?: Martin Koebel (Canada)
  • TRUST Update: Sven Mahner (Germany)
  • NACT Proponent: Anna Fagotti (Italy); PDS Proponent: Dennis Chi (USA)
  • Vignette Presentation: Robert Coleman (USA)
  • HRD Positive: David O’Malley (USA)
  • HRP BRCA Neg: Shannon Westin (USA)
  • Platinum Sensitive Recurrence at 12 Months: What’s next? Who Benefits from PARP in the Recurring Setting?: Rosalind Glasspool (UK)
  • Molecular Testing for Initial Therapy; Beyond BRCA: Charlie Gourley (UK)
  • Biomarkers for Immunotherapy Response: Brad Nelson (Canada)

Master Session: Uterine Cancer

  • Chairs: Pernille Jensen (Denmark), Andrea Mariani (USA), Matthew Powell (USA)
  • Sentinel LN is Positive on Frozen Section: Full Dissection vs "Why did I Send for Frozen?": Edward Tanner (USA)
  • Sufficient Evidence to Implement SLN in Women with EC, High Risk Histology - Risk of Missing Paraaortic LN Metastases: Emma Rossi (USA)
  • Case Set Up with Controversy: Andrea Mariani (USA)
  • What to do with ITC and Micro Metastasis in SLN on Final Pathology: Marie Plante (Canada)
  • No Need for Adjuvant Treatment or Send for the Chemo & Radiation? Or in the Middle?: Floor Backes (USA)
  • Debate: Molecular Profiling for Postop Risk Stratification & Adjuvant Treatment Decisions of Women with Early Stage EC; Ready: Jessica McAlpine (Canada) vs Not Ready: Remi Nout (The Netherlands)
  • Panelist: Anuja Jhingran (USA)
  • Where are We Today & Where are We Going in the Treatment of Women with Advanced/Recurrent EC?: Mansoor Mirza (Denmark)

Master Session: Vulvar Cancer

  • Chairs: Michael Höckel (Germany), Benedetti Panici (Italy), Ate van der Zee (The Netherlands)
  • Current Insights in the Etiology & Pathogenesis of Vulvar Cancer: HPV Infection - Predisposing Conditions - Premalignant Disease - Overt Malignancy: Joanne de Hullu (The Netherlands)
  • Debate: Early Stage Vulvar Cancer: An Overview of Current Standard of Surgical Care vs Cancer Field Surgery for Vulvar Carcinoma as Alternative Approach: Maaike Oonk (The Netherlands) vs Nadja Dornhöfer (Germany)
  • Role of Adjuvant Therapy in Primary Treatment of Vulvar Cancer: Linn Wölber (Germany)

Plenary I: Oral Abstract Presentations

  • Moderator: Nicoletta Colombo (Italy)
  • Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial: Jonathan Ledermann (United Kingdom)
  • Efficacy and Safety of Lenvatinib Plus Pembrolizumab in Patients with Previously Treated Ovarian Cancer in the Multicohort Phase 2 LEAP-005 Study: Antonio González-Martín (Spain)
  • Postprogression Efficacy Outcomes From the Phase 3 ARIEL3 Study of Rucaparib in Patients With Platinum-Sensitive Recurrent Ovarian Carcinoma Associated With Either BRCA1 or BRCA2 Mutations: Johanne Weberpals (Canada)
  • Distillation: Kathleen Moore (USA)

Plenary II: Oral Abstracts Presentations

  • Moderators: Matthew Powell (USA), Rene Pareja (Colombia)
  • Refining Pathologic Interpretation of Endometrial Carcinomas: Lessons Learned from a Nationwide Study in a new Era of Molecular Classification: Emily Thompson (Canada)
  • Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study: Soyoun Rachel Kim (Canada)
  • Variation in practice in endometrial cancer (EC); can molecular classification direct care and reduce costs associated with management?: Emily Thompson (Canada)
  • Sentinel lymph node biopsy versus lymphadenectomy for intermediate and high grade endometrial cancer staging (SENTOR trial): A prospective multicenter cohort study: Maria Cusimano (Canada)
  • A multicentric randomized trial to evaluate the ROle of uterine MANipulator on laparoscopic/robotic HYsterectomy for the treatment of low-risk endometrial cancer: the ROMANHY Trial (NCT:02762214): Salvatore Gueli Alletti (Italy)
  • Frailty is Independently Associated with Worse Outcomes and Increased Resource Use Following Procedures to Treat Endometrial Cancer: Morcos Nakhla (USA)

Plenary III: Oral Abstract Presentations

  • Moderators: Paula Wimberger (Germany), Qinglei Gao (China)
  • The learning curve of robot-assisted laparoscopy has impact on the oncological outcomes of early stage cervical cancer patients: Isle Baeten (Netherlands)
  • Oncologic Outcomes and Role of Adjuvant Therapy in Endometrial Cancer Patients with Low Volume Metastasis in the Sentinel Lymph Nodes: An International Multi-Institutional Study: Andrea Mariani (USA)
  • Oncolytic Vaccinia (Olvi-Vec) Primed Immunochemotherapy in Platinum Resistant/Refractory Ovarian Cancer: Robert Holloway (USA)
  • Efficacy on Individualized Starting Dose (ISD) and Fixed Starting Dose (FSD) of Niraparib per Investigator-Assessment (IA) in Newly Diagnosed Advanced Ovarian Cancer (OC): Whitney Graybill (USA)
  • Distillation: Asima Mukhopadhyay (India)

Presidential Plenary IV

  • Presidential Address: Roberto Angioli (Italy)
  • World Ovarian Cancer Coalition Global Ovarian Cancer Charter Launch: Elisabeth Baugh (Canada), Frances Reid (UK)
  • Global Outreach & Engagement Initiatives of the International Gynecologic Cancer Society: Dicey Jackson Scroggins (USA)
  • Business Meeting: Roberto Angioli (Italy)

Plenary V: Oral Abstract Presentations

  • Moderators: David Atallah (Lebanon), Andreas Obermair (Australia)
  • Phase II trial evaluating efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer: Nobumichi Nishikawa (Japan)
  • Randomized Double-Blind Placebo Controlled Trial of Frontline Maintenance Vigil Immunotherapy (VITAL study) in Stage III/IV Ovarian Cancer: Efficacy Assessment in BRCA1/2-wt Patients: Rodney Rocconi (USA)
  • Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer: Angeles Alvarez Secord (USA)
    Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial: Gilles Freyer (USA)
  • Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higherand lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial: Philipp Harter (Germany)
  • IGCS Home
  • Education Portal Home

Copyright ©2023 International Gynecologic Cancer Society. All rights reserved.